Schuster Angela, Tigges Paula, Grune Julianna, Kraft Judith, Greser Alexandra, Gágyor Ildikó, Böhme Mandy, Klingeberg Anja, Eckmanns Tim, Maun Andy, Mentzel Anja, Schmiemann Guido, Heintze Christoph, Bleidorn Jutta
Institute of General Practice and Family Medicine, Charité - Universitätsmedizin Berlin, 10117, Berlin, Germany.
Department of General Practice, University Hospital Wuerzburg, Josef- Schneider-Str. 2, D7, 97080, Wuerzburg, Germany.
BMC Health Serv Res. 2025 Aug 30;25(1):1160. doi: 10.1186/s12913-025-13218-2.
Urinary tract infections are common and lead to frequent and inappropriate antibiotic prescribing in primary care. The RedAres randomized controlled trial has shown to reduce second-line antibiotic use for urinary tract infections through a multimodal intervention. It included guideline recommendations for general practitioners and patients (1), provision of regional data for antibiotic resistance (2), delivering personalized feedback based on the proportion of first- and second-line antibiotic prescriptions (3), and benchmarking with regional or supra-regional practices (4). To discuss all interventions, individual telephone counselling was offered. The aim of the RedAres process evaluation is to assess the acceptability of the multimodal intervention among general practitioners and the feasibility of the study design for medical practice assistants.
The general practitioners and medical practice assistants surveys were conducted following the RedAres intervention during the last trial visit. To assess acceptability among general practitioners, we developed a questionnaire based on Sekhon´s theoretical framework of acceptability. The questionnaires for medical practice assistants included questions on data management feasibility and attitudes towards this task. Data were analyzed using SPSS and R. Cases were weighted according to the number of respondents per practice, descriptive statistics, chi-squared tests, bivariable logistic regressions, and multivariable logistic regressions were used for data analysis.
The response rate to the questionnaires was 96.6% for general practitioners ( = 63) and 91.5% for medical practice assistants ( = 56). Most general practitioners (93.9%) found the multimodal intervention to be adequate for enhancing guideline adherence. Among the intervention components, resistance data (31.8%) and prescribing feedback (31.8%) were equally appreciated, while benchmarking (12.2%) was the least appreciated intervention. Most medical practice assistants (96.3%) reported being satisfied with the data collection, documentation, and transfer in the RedAres study.
The RedAres intervention was favorably received by general practitioners, medical practice assistants deemed data management and extraction feasible. With the backdrop of the intervention’s effectiveness, its favorable reception, and its practicability, antibiotic stewardship and quality control measures implemented at the practice level hold promise for effectively enhancing guideline adherence and improving antibiotic stewardship practices in real-world settings.
Prospective registration at the German Clinical Trial Register (DRKS), trial number DRKS00020389, registration date 30.01.2020 (https//drks.de/search/en/trial/DRKS00020389).
The online version contains supplementary material available at 10.1186/s12913-025-13218-2.
尿路感染很常见,在初级医疗保健中导致频繁且不适当的抗生素处方。RedAres随机对照试验已表明,通过多模式干预可减少尿路感染的二线抗生素使用。该试验包括针对全科医生和患者的指南建议(1)、提供抗生素耐药性的区域数据(2)、根据一线和二线抗生素处方比例提供个性化反馈(3)以及与区域或超区域医疗机构进行基准对比(4)。为讨论所有干预措施,还提供了个人电话咨询。RedAres过程评估的目的是评估多模式干预在全科医生中的可接受性以及该研究设计对医疗实践助理的可行性。
在RedAres干预后的最后一次试验访视期间,对全科医生和医疗实践助理进行了调查。为评估全科医生的可接受性,我们基于Sekhon的可接受性理论框架编制了一份问卷。医疗实践助理的问卷包括有关数据管理可行性以及对该任务态度的问题。使用SPSS和R软件对数据进行分析。根据每个医疗机构的受访者数量对病例进行加权,采用描述性统计、卡方检验、双变量逻辑回归和多变量逻辑回归进行数据分析。
全科医生对问卷的回复率为96.6%(n = 63),医疗实践助理的回复率为91.5%(n = 56)。大多数全科医生(93.9%)认为多模式干预足以提高对指南的依从性。在干预组成部分中,耐药性数据(31.8%)和处方反馈(31.8%)同样受到重视,而基准对比(12.2%)是最不受重视的干预措施。大多数医疗实践助理(96.3%)报告对RedAres研究中的数据收集、记录和传输感到满意。
RedAres干预受到了全科医生的好评,医疗实践助理认为数据管理和提取是可行的。鉴于该干预措施的有效性、良好的接受度和实用性,在实践层面实施的抗生素管理和质量控制措施有望在现实环境中有效提高对指南的依从性并改善抗生素管理实践。
在德国临床试验注册中心(DRKS)进行前瞻性注册,试验编号DRKS00020389,注册日期2020年1月30日(https//drks.de/search/en/trial/DRKS00020389)。
在线版本包含可在10.1186/s12913 - 025 - 13218 - 2获取的补充材料。